NCT02256098

Brief Summary

The PFC Sigma Knee by DePuy Synthes is an excellent knee replacement with an excellent clinical track record, good survival rates (98% 10 years survival in patients aged \< 55 years)(Keenan et al., 2012) and minimal early migration as measured with RSA (0.5mm MTPM at two years follow-up)(von et al., 2009). The ATTUNE™ Knee by DePuy Synthes is an advancement in knee replacement options. It is designed to provide better range of motion and address the unstable feeling some patients experience during everyday activities, such as stair descent and bending. To date (March 2013), more than 3,500 patients have received an ATTUNE Knee as part of a limited launch and positive feedback was received regarding patient recovery, stability and motion. The objective of this study is to accurately assess and compare migration, clinical and radiological outcome and patient reported outcomes of two TKR prostheses: the Cemented ATTUNE™ Fixed Bearing Cruciate Retaining Knee System and the Cemented PFC Sigma Fixed Bearing Cruciate Retaining Knee System, both by DePuy Synthes, Warsaw, Indiana, USA. The primary objective of this study is to compare the magnitude and pattern of migration of the prostheses (Femoral and Tibial component). The secondary objective of this study is to compare clinical and radiological outcome of the prostheses and PROMS. The tertiary objective of this study is to compare clinical and radiological outcome and PROMS of the prostheses with migration data. This study is designed as a single-blind, randomized trial between the ATTUNE™ Knee System and PFC Sigma Knee System. 32 patients with the ATTUNE™ Knee System and 32 patients with PFC Sigma Knee System will be included in this study. The study population will consist of patients with symptomatic osteoarthritis of the knee scheduled for TKR surgery at the Department of Orthopaedics, Medisch Centrum Haaglanden, The Hague, The Netherlands. Annually 300 TKA procedures are performed in this department, of which about 90% is Osteo Arthritis (OA) and 10% Rheumatoid Arthritis (RA) and other indications. We anticipate that inclusion can be accomplished within a 1 year period and that the total study duration is 3 years. Main study parameters/endpoints are:

  • Migration of the prosthesis with respect to the host bone measured by means of roentgen stereophotogrammetric analysis (RSA).
  • Patient Reported Outcome Measures by means of questionnaires.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

September 23, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 3, 2014

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 2, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2017

Completed
Last Updated

February 1, 2018

Status Verified

January 1, 2018

Enrollment Period

3.2 years

First QC Date

September 23, 2014

Last Update Submit

January 30, 2018

Conditions

Keywords

Comparative StudyKnee ProsthesisProsthesis DesignTreatment OutcomeFollow-Up StudiesArthroplasty, Replacement, Knee/methods

Outcome Measures

Primary Outcomes (1)

  • Migration, measured by means of RSA.

    Migration (MTPM in mm) of the prosthesis with respect to the host bone measured by means of roentgen stereophotogrammetric analysis (RSA).

    2 Years

Secondary Outcomes (4)

  • EQ-5D

    2 Years

  • KOOS

    2 Years

  • VAS pain

    2 Years

  • 2 Anchor questions

    2 Years

Study Arms (2)

ATTUNE™

EXPERIMENTAL

Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy

Device: ATTUNE™ Knee Prosthesis by DePuy

PFC Sigma

ACTIVE COMPARATOR

Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy

Device: PFC Sigma Knee Prosthesis by DePuy

Interventions

Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy

ATTUNE™

Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy

PFC Sigma

Eligibility Criteria

Age21 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is diagnosed with osteoarthritis or rheumatoid arthritis and requiring primary knee arthroplasty
  • All consecutive patients ("usual care") are included to prevent selection bias in the migration analysis.
  • Patient is capable of giving informed consent and expressing a willingness to comply with this study

You may not qualify if:

  • The patient has an a-priori risk for a posterior-stabilized total knee arthroplasty.
  • Insufficiency of the posterior cruciate ligament (PCL)
  • Status after patellectomy
  • In case flexion is less than 90 degrees
  • When it is expected that the tibia cut during surgery will compromise the attachment of the PCL (because of bony defects)
  • The patient is unable or unwilling to sign the Informed Consent specific to this study
  • The patient does not understand the Dutch or English language good enough to participate
  • Patients indicated for revision arthroplasty

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Leiden University Medical Center

Leiden, 2300RC, Netherlands

Location

Medisch Centrum Haaglanden

The Hague, 2501CK, Netherlands

Location

MeSH Terms

Conditions

Joint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Rob G Nelissen, Prof. PhD, MD

    Dep. Orthopaedics, Leiden University Medical Center

    PRINCIPAL INVESTIGATOR
  • Edward R Valstar, Prof. PhD. MSc

    Dep. Orthopaedics, Leiden University Medical Center

    PRINCIPAL INVESTIGATOR
  • Peter H den Hollander, MD

    Dep. Orthopaedics, Medisch Centrum Haaglanden

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. PhD MD Head of the Department of Orthopaedics

Study Record Dates

First Submitted

September 23, 2014

First Posted

October 3, 2014

Study Start

September 1, 2014

Primary Completion

November 2, 2017

Study Completion

November 2, 2017

Last Updated

February 1, 2018

Record last verified: 2018-01

Locations